SS
Silvia Stacchiotti
Highly rated in
29
conditions

Silvia Stacchiotti

GSK Investigational Site
Italy
Highly rated in
29
conditions
Clinical Trials:Currently Recruiting for 7 Trials
Highly rated in
29
conditions
About|Expertise|Location|Research
Areas of Expertise

Many experts have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a expert treats and their level of experience.

Check Silvia Stacchiotti's experience treating your condition:
About Silvia Stacchiotti

Silvia Stacchiotti practices in Milano, Italy. Stacchiotti is highly rated in 29 conditions, according to our data. Her top areas of expertise are Solitary Fibrous Tumor, Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Alveolar Soft Part Sarcoma, and Synovectomy.

Her clinical research consists of co-authoring 217 peer reviewed articles and participating in 16 clinical trials in the past 15 years.

Locations
Milano, 20133, IT
Background & Education
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Enrollment Status: Recruiting
Publish Date: November 18, 2021
Intervention Type: Drug
Study Drugs: SunitinibNivolumab
Study Phase: Phase 1/Phase 2
Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma
Enrollment Status: Recruiting
Publish Date: November 01, 2021
Intervention Type: Drug
Study Drug: TSR-042
Study Phase: Phase 2
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2021
Intervention Type: Drug
Study Drugs: TrabectedinAdriamycinDacarbazine
Study Phase: Phase 2
Breast Sarcomas: A Retrospective Analysis of Clinical Features and Outcomes
Enrollment Status: Recruiting
Publish Date: November 01, 2021
Intervention Type: Other
ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)
Enrollment Status: Recruiting
Publish Date: November 01, 2021
Intervention Type: Drug
Study Drug: Eribulin
Study Phase: Phase 2
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Enrollment Status: Recruiting
Publish Date: November 01, 2021
Intervention Type: Drug
Study Drugs: TrabectedinOlaparib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Active, not recruiting
Publish Date: November 03, 2022
Intervention Type: Drug
Study Drugs: AnlotinibDecarbazine
Study Phase: Phase 3
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active, not recruiting
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drugs: Letetresgene AutoleucelFludarabineCyclophosphamide
Study Phase: Phase 2
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Active, not recruiting
Publish Date: May 11, 2022
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Active, not recruiting
Publish Date: December 07, 2021
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 08, 2021
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Enrollment Status: Active, not recruiting
Publish Date: November 05, 2021
Intervention Type: Drug
Study Drug: Trabectedin
Study Phase: Phase 2
Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor
Enrollment Status: Completed
Publish Date: September 28, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: September 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials -
217 Total Publications
Corrigendum to "SELNET clinical practice guidelines for bone sarcoma" Critical reviews in oncology/hematology, vol. 174 (2022), 1-10.
Journal: Critical reviews in oncology/hematology
Published: October 11, 2022
Save this expert for later
Sign Up
Looking for the best expert for you?
Start Here
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more